CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-03 | Li Dean Y Director | Grant or award · Stock Option (Right to Buy) | +26,193 | 26,193 | ||
| 2024-05-30 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +3,000 | $1.06 | $3K | 538,457 |
| 2024-05-30 | Marriott Tina President and COO | Sale 10b5-1 | −3,000 | $8.78 | $26K | 535,457 |
| 2024-05-30 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −0 | 482,000 | ||
| 2024-05-28 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $9.17 | $105K | 7,186,913 |
| 2024-05-15 | Marriott Tina President and COO | Shares withheld for taxes | −9,998 | $10.01 | $100K | 533,233 |
| 2024-05-15 | Mauro David J Chief Medical Officer | Shares withheld for taxes | −867 | $10.01 | $9K | 243,762 |
| 2024-05-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −26,082 | $10.01 | $261K | 808,738 |
| 2024-05-15 | Secora Michael Chief Financial Officer | Shares withheld for taxes | −11,962 | $10.01 | $120K | 1,219,093 |
| 2024-05-14 | Borgeson Blake Director | Sale 10b5-1 | −20,054 | $10.12 | $203K | 7,198,360 |
| 2024-05-02 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −28,704 | $8.47 | $243K | 834,820 |
| 2024-05-02 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +21,296 | 856,116 | ||
| 2024-05-02 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −21,296 | $8.47 | $180K | 834,820 |
| 2024-05-02 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −21,296 | 6,426,700 | ||
| 2024-05-01 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −25,000 | 913,524 | ||
| 2024-05-01 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −50,000 | $7.73 | $387K | 863,524 |
| 2024-04-30 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $7.95 | $91K | 7,218,414 |
| 2024-04-25 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +3,000 | $1.06 | $3K | 546,231 |
| 2024-04-25 | Marriott Tina President and COO | Sale 10b5-1 | −3,000 | $7.67 | $23K | 543,231 |
| 2024-04-25 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,000 | 485,000 |
Page 20 of 41 · 805 trades